Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 94

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 94
---

Through our wholly owned subsidiary, MRNA Scientific, we engage in the application of genomic testing to enable early disease diagnosis and support proactive health management.

MRNA Scientific's principal office address is Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jln Bangsar Utama 1, Kuala Lumpur, Malaysia. Our molecular genomic lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia, and we have a colon cancer and infectious diseases screening lab located at 4th floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia. MRNA Scientific's telephone number is (+6018-2218762) and website is www.bionexusgenelab.com.

 11Table of Contents

Our Non-invasive Blood Tests

MRNA Scientific develops and markets safe, effective, and non-invasive blood tests designed to detect diseases at early stages. These tests aim to reduce treatment costs and improve patient outcomes.

Our blood-based assays analyze changes in ribonucleic acid (RNA) to assess specific risks and detailed aspects of an individual’s health condition. These tests currently screen for:

 ·Eight types of cancer: nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon; ·Two inflammatory bowel diseases: ulcerative colitis and Crohn’s disease; ·Osteoarthritis; ·Cardiovascular and neurological risks, including heart attack, stroke, and mental disorders (added in 2023/2024).

We believe our genomic screening can enhance the accuracy of traditional diagnostic procedures such as imaging and biopsies, serving as a valuable complementary tool.

We generate revenue by screening blood samples collected by third-party healthcare providers including doctors, labs, and hospitals using proprietary biomarkers developed in-house. We believe MRNA Scientific is currently the only commercial molecular lab in Malaysia offering RNA-based diagnostic testing for cancer, inflammatory bowel disease, and osteoarthritis, using a GeneChip platform certified by the U.S. Food and Drug Administration (FDA). Our screening results also support personalized medicine by informing customized therapies tailored to each patient’s risk profile.

Development of Screening Process

Our late co-founder, Dr. Choong-Chin Liew, pioneered a novel approach to RNA-based diagnostics by identifying circulating blood biomarkers that reflect tissue-level disease processes. His research demonstrated that gene expression in peripheral blood can change in response to injury or illness, providing molecular insight into disease